Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing continued investor concern because a wave of law-firm announcements highlighted an ongoing securities class action tied to disclosures about its lead drug candidate, deramiocel. The legal publicity is adding pressure and volatility to a stock that has already fallen sharply from its 52-week high.

• Positive Sentiment: B. Riley Financial upgraded Capricor Therapeutics to Buy, while a separate report said the consensus price target increased to approximately $21.42. These analyst views provide a potential counterweight to the litigation-related selling pressure. Capricor Therapeutics Raised to Buy at B. Riley Financial Capricor Therapeutics Consensus Price Target Increased
• Neutral Sentiment: Multiple firms, including Rosen, Hagens Berman, Kaplan Fox, and others, reminded investors that September 28, 2026 is the deadline to seek lead-plaintiff status in the securities class action. These releases largely repeat existing information rather than announce a new company development. Rosen Law Firm Capricor Deadline Notice Kaplan Fox Capricor Class Action Notice
• Negative Sentiment: The class-action allegations claim Capricor may have misled investors about the progress of the deramiocel biologics license application and failed to disclose that the final statistical analysis plan for the HOPE-3 trial had not been agreed upon with the FDA. The complaints cite adverse FDA briefing documents and an unfavorable advisory committee vote, which allegedly triggered a severe prior share-price decline. The allegations have not been proven, but the litigation creates legal, reputational, and regulatory overhang for CAPR. Capricor Shareholder Alert Bleichmar Fonti Capricor Class Action Announcement